Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellaVision ABCLVSF 89 EV-to-EBITDA is 20.28 as of Aug. 04, 2026, which is 48% below its 10-year median of 39.15. GuruFocus rates CLVSF with a GF Score™ of 89/100 and a GF Value™ of $19.71 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 512 Medical Devices & Instruments companies, CellaVision AB ranks worse than 67.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CellaVision AB's enterprise value is $358.58 Mil.
CellaVision AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $17.69 Mil. Therefore, CellaVision AB's EV-to-EBITDA for today is 20.28.
The historical rank and industry rank for CellaVision AB's EV-to-EBITDA or its related term are showing as below:
CLVSF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.85 Med: 39.15 Max: 89.58
Current: 19.68
During the past 13 years, the highest EV-to-EBITDA of CellaVision AB was 89.58. The lowest was 14.85. And the median was 39.15.
CLVSF's EV-to-EBITDA is ranked worse than 67.38% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.44
vs CLVSF: 19.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CellaVision AB (OTCPK:CLVSF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CellaVision AB's PE Ratio (TTM) for today is calculated as:
CellaVision AB's share price for today is $14.00.
CellaVision AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.578.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CellaVision AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CellaVision AB's EV-to-EBITDA falls into.
CellaVision AB's current Enterprise Value is $358.58 Mil.
CellaVision AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CLVSF) has a EV-to-EBITDA of 20.28 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CellaVision AB. This is 48% below median its historical median of 39.15. Over the past decade, CellaVision AB's EV-to-EBITDA has ranged from 14.85 to 89.58. According to the industry distribution chart, CellaVision AB ranks #345 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 67.4%.
Is CellaVision AB's EV-to-EBITDA too high?
CellaVision AB's current EV-to-EBITDA of 20.28 is 48% below median its 10-year median of 39.15. Over the past 10 years, this metric has ranged from a low of 14.85 to a high of 89.58. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.44. CellaVision AB's value of 20.28 is 40.4% above this industry median. Based on the distribution chart, CellaVision AB ranks #345 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #345 out of 512 companies for EV-to-EBITDA. This places CellaVision AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.44. CellaVision AB's value of 20.28 is 40.4% above this benchmark. Historically, CellaVision AB's own EV-to-EBITDA has ranged from 14.85 to 89.58 over the past decade. While the company's 10-year median is 39.15 vs. the industry median of 14.44, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.44, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current EV-to-EBITDA of 20.28 is 40.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CellaVision AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current EV-to-EBITDA is 20.28, which is 48% below median its own 10-year median of 39.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CLVSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $19.71, compared to a current price of $14.00 — trading 29% below its estimated fair value. The current EV-to-EBITDA is 20.28, which is 48% below median its 10-year median of 39.15 and 40.4% above the Medical Devices & Instruments industry median of 14.44. CellaVision AB's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CellaVision AB (CLVSF), the current EV-to-EBITDA is 20.28 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CLVSF) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $14.00 is trading 29% below its estimated GF Value™ of $19.71.
GuruFocus considers CellaVision AB to be Modestly Undervalued.
Key valuation signals for CLVSF:
EV-to-EBITDA: 20.28 (48% below median its 10-year median of 39.15)
GF Value™: $19.71 vs. price of $14.00 (29% below fair value)
Industry Position: 40.4% above the Medical Devices & Instruments median (#345 of 512)
No single metric tells the full story. See the CLVSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
89GF Score
Get the complete analysis for CLVSF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVSF has been successfully added to your 
